Therapeutic vaccination against human papilloma virus induced malignancies

Author(s):
Burg, S.H. van der (0000-0002-6556-0354); Melief, C.J.M.
Published
2011
Publication type
Article / Letter to editor

Abstract

Human Papilloma Virus (HPV)-induced (pre-)malignancies offer an excellent case for the rational design of immunotherapeutic strategies against cancer. Transformed cells express tumor-specific antigens of viral origin while the spontaneous antitumor response and the immunological make up of HPV-induced tumors do not differ from other immunogenic epithelial tumors. A first clinically active therapeutic HPV vaccine has been developed and clear links were found between the type and kinetics of vaccine-induced T-cell immunity. Here, we will review the mechanisms determining the success and failure of therapeutic vaccines against HPV-induced tumors, with particular emphasis on the immunological setting in which these vaccines need to work. The recent progress in therapeutic HPV vaccination will guide the development of successful vaccines in other diseases.

regulatory t-cells cervical-cancer patients vulvar intraepithelial neoplasia phase-ii trial immune-responses dna vaccination ifn-gamma tumor lesions expression
Date issued
2011-04-30
Language
English
Is part of
Current Opinion in Immunology (2011), Vol. 23, no. 2, p. 252-257
hdl
1887/109326
doi
10.1016/j.coi.2010.12.010